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Upon viral infection, cells undergo apoptosis as a defense against viral replication. Viruses, in turn, have evolved
elaborate mechanisms to subvert apoptotic processes. Here, we report that a novel viral mitochondrial anti-apoptotic
protein (vMAP) of murine c-herpesvirus 68 (cHV-68) interacts with Bcl-2 and voltage-dependent anion channel 1
(VDAC1) in a genetically separable manner. The N-terminal region of vMAP interacted with Bcl-2, and this interaction
markedly increased not only Bcl-2 recruitment to mitochondria but also its avidity for BH3-only pro-apoptotic proteins,
thereby suppressing Bax mitochondrial translocation and activation. In addition, the central and C-terminal
hydrophobic regions of vMAP interacted with VDAC1. Consequently, these interactions resulted in the effective
inhibition of cytochrome c release, leading to the comprehensive inhibition of mitochondrion-mediated apoptosis.
Finally, vMAP gene was required for efficient cHV-68 lytic replication in normal cells, but not in mitochondrial
apoptosis-deficient cells. These results demonstrate that cHV-68 vMAP independently targets two important
regulators of mitochondrial apoptosis-mediated intracellular innate immunity, allowing efficient viral lytic replication.
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Introduction
Apoptosis, or programmed cell death, has a key role in a
variety of eukaryotic biological processes such as develop-
ment and immune responses. Whether initiated by receptor
ligation at the cell surface or through signal transduction
from intracellular organelles, both caspase-dependent and -
independent apoptotic pathways degrade cellular compo-
nents, leading to the complete dismantling of targeted cells.
Particularly, mitochondria serve as gatekeepers for the life-
or-death decision, conveying apoptotic signals by releasing
death-promoting factors (e.g., cytochrome c, apoptosis-
inducing factor, and DIABLO/Smac from the intermembrane
space [1–4]).
Recent studies have largely elucidated the complex
mechanism that eukaryotes have evolved to regulate the
permeability of the mitochondrial outer membrane during
apoptosis, particularly with regard to Bcl-2 homology (BH)
family proteins [5–7]. Bcl-2 family members are classiﬁed as
either anti-apoptotic (e.g., Bcl-2, Bcl-xL, Bcl-w, and A1) or
pro-apoptotic, the latter of which can be further divided into
the multi-BH domain and BH3-only subgroups. Similar to
anti-apoptotic proteins, the multi-BH domain members, such
as Bax and Bak, adopt a globular fold consisting of up to nine
a-helices that form an extended hydrophobic cleft on the
surface [8]. This cleft serves as an authentic BH3-binding site
that mediates their translocation and oligomerization within
the mitochondrial outer membrane and, ultimately, mito-
chondrial permeabilization [6,9].
Additional regulation of the mitochondrion-dependent
apoptosis is mediated by the permeability transition pore
(PTP), a complex composed of the voltage-dependent anion
channel (VDAC) and adenine nucleotide translocator (ANT).
VDAC is located in the mitochondrial outer membrane, and
its transmembrane can form a barrel with a pore size
consistent with the estimated open-channel diameter to
allow the escape of cytochrome c. A direct interaction
between Bcl-2 family members and VDAC may control
cytochrome c permeation across membranes [7,10]. Alter-
natively, VDAC-mediated closure of the PTP supercomplex
may prevent ATP/ADP exchange across the membrane, which
ultimately results in outer membrane permeabilization and
subsequent release of pro-apoptotic factors from the inter-
membrane space; this, in turn, triggers apoptosis in the
cytoplasm or nucleus [10]. Although current studies favor the
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in deﬁning the nature of the PTP complex.
Apoptosis is part of host innate immunity that eliminates
the propagation of intracellular pathogens such as viruses. As
a countermeasure, viruses have evolved to encode numerous
open reading frames (ORFs) to circumvent cellular apoptotic
pathways. Herpesviruses, particularly c-herpesviruses, includ-
ing human Epstein-Barr virus, Kaposi sarcoma–associated
herpesvirus, and murine c-herpesvirus 68 (cHV-68), provide
unique models for dissecting the molecular mechanisms of
apoptotic regulation. A common aspect of these c-herpesvi-
ruses is that they encode viral homologs of Bcl-2, designated
vBcl-2, and these vBcl-2 genes effectively prevent cells from
undergoing apoptosis upon various stress responses [11,12].
vBcl-2 has been speculated to serve a vital role in the virus
lifecycle by inhibiting the premature apoptotic death of host
cells during acute replication, allowing completion of viral
replication cycle and favoring the spread of progeny virus.
However, the previous studies have found that cHV-68 vBcl-2
has no role during acute infection but its activity is critical
speciﬁcally to latent infection [13–15]. Thus, to identify viral
protein that evades host apoptosis-mediated innate immunity
during acute infection, we searched for mitochondrial
proteins within the cHV-68 genome. We report that viral
mitochondrial anti-apoptosis protein (vMAP) speciﬁcally
interacts with cellular Bcl-2/Bcl-xL and VDAC and that these
interactions effectively dampen host apoptotic processes,
which ultimately contributes to efﬁcient lytic replication in
culture.
Results
The cHV-68 vMAP Gene Encodes a Mitochondrial Anti-
Apoptotic Protein
To test the role of the mitochondrion-dependent apoptosis
in cHV-68 replication, wild-type (wt) and Bax
 / Bak
 / double
knockout (DKO) murine embryonic ﬁbroblasts (MEFs) were
infected with a GFP-containing cHV-68 (cHV-68DK3-GFP).
DKO MEFs supported cHV-68DK3-GFP replication with
accelerated kinetics as compared with wt MEFs: the virus
titer in DKO MEFs was 50–100 times higher than that in wt
MEFs (Figure S1A and S1B). Furthermore, as previously
shown [16], DKO MEFs displayed markedly reduced cell death
upon cHV-68 replication than did wt MEF (Figure S1C and
S1D). These results indicate that mitochondrion-mediated
apoptosis plays a negative role in cHV-68 lytic replication,
suggesting that cHV-68 needs to deregulate this pathway to
maximize its propagation. To search for the potential
mitochondrial protein(s) encoded by cHV-68, we employed
two computer programs, MITOProt (http://mips.gsf.de/
cgi-bin/proj/medgen/mitoﬁlter) and PSORT (http://psort.
nibb.ac.jp/), which assess the likelihood of each candidate
viral gene product to be targeted to the mitochondrion. This
survey identiﬁed an M8 gene product [17] that we have
named vMAP. vMAP is present in the second exon of ORF57
and shares the identical nucleotide sequence with ORF57
(Figure 1A). However, vMAP has a þ1 shift in reference to
ORF57 frame, thus encoding a polypeptide of distinct amino
acid sequence from ORF57. vMAP contains 157 amino acids,
with a predicted mitochondrial targeting sequence (MTS) at
its N-terminus and a putative transmembrane domain at its
C-terminus (Figure 1B). vMAP protein was readily detected
during cHV-68 lytic replication with an apparent molecular
weight of 16 kDa (Figure 2A, left panel). However, we failed to
detect vMAP protein in cHV-68 latently infected S11 cells
under the same conditions (unpublished data). When vMAP
expression vector was transfected into NIH3T3 cells, how-
ever, vMAP migrated as 7-, 14-, and 16-kDa species (Figure
2A, right panel). Mutational analyses indicated that the 7- and
14-kDa proteins were derived from translational initiation at
the third (Met70) and second (Met21) internal initiation codon,
respectively (unpublished data). Intracellular fractionation
demonstrated that vMAP was present exclusively in the
mitochondrion-enriched heavy membrane (HM) fraction
(Figure 2A, right panel). The position and integrity of the
fraction was conﬁrmed by the presence of the mitochondrial
resident protein COX4. Confocal immunoﬂuorescence mi-
croscopy also showed that vMAP was present in the cytoplasm
extensively colocalized with MitoTracker, a dye that specif-
ically labels mitochondria in living cells, and with Hsp60 and
cytochrome c mitochondrial resident proteins (Figures 2B,
S2A, and S2C). GFP fusions containing the N-terminal region
of vMAP were constructed to deﬁne the MTS of vMAP. The
N-terminal 40 residues of vMAP were sufﬁcient to target GFP
to mitochondria (Figure 2C). Interestingly, this N-terminal
sequence of vMAP is predicted to contain a-helical structure,
followed by a stretch of positively charged residues that are
the potential MTS motif (Figure 1A). In fact, deletion
mutations within this motif considerably impaired the
mitochondrial localization of GFP fusions containing vMAP
N-terminal sequences in confocal microscopy and intra-
cellular fractionation (Figures 2C and S2B). Of note, the
vMAP(1–30)-GFP and vMAP(21–49)-GFP also showed the
nuclear localization, which was likely contributed by GFP
fusion (Figure 2C). These results indicate that the N-terminal
40 residues are sufﬁcient for mitochondrial targeting activity.
To assess vMAP function in apoptosis, polyclonal NIH3T3/
puro and NIH3T3/vMAP stable cell lines were established.
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Author Summary
Apoptosis is a conserved cell death program that contributes to
restriction of viral replication and elimination of infected cells.
Whether triggered via internal inducers such as DNA damage or via
external stimuli such as engagement of the death receptor,
apoptosis takes place through a cascade of regulated internal
proteolytic digestion, resulting in a collapse of cellular infrastructure,
mitochondrial potential, genomic fidelity, and cell membrane
integrity. Indeed, apoptosis represents a predominant form of
virally infected cell demise. In response, viruses have evolved
numerous ways of circumventing this host-cell apoptosis. Most of
the DNA viruses including murine c-herpesvirus 68 (cHV-68) are
genetically equipped with anti-apoptotic ability to ensure viral
replication and propagation. The authors have identified a new viral
mitochondrial protein (vMAP) of cHV-68 that interacts with Bcl-2
and voltage-dependent anion channel 1 (VDAC1) in a genetically
separable manner. These interactions markedly suppress Bax
mitochondrial translocation and activation and inhibit cytochrome
c release, leading to the comprehensive inhibition of mitochond-
rion-mediated apoptosis. The authors also demonstrate that vMAP
gene is required for efficient cHV-68 lytic replication in normal cells,
but not in mitochondrial apoptosis-deficient cells. These findings are
entirely novel and significantly advance our understanding of how
virus escapes host intracellular apoptosis-mediated innate immun-
ity.The expression of vMAP was conﬁrmed by immunoblotting
with anti-vMAP serum as shown in Figure 2D. These cells
were treated with various apoptotic agents and stresses
(staurosporine [ST], TNF-a, vesicular stomatitis virus infec-
tion, and nocodazole) to induce apoptosis, stained with
propidium iodide (PI), and then analyzed by ﬂow cytometry.
vMAP expression signiﬁcantly reduced the accumulation of
sub-G1 cells that are considered to be apoptotic (Figure 2D
and 2E). These results demonstrate that cHV-68 vMAP has
robust anti-apoptotic activity toward various apoptotic
agents.
vMAP Interaction with Bcl-2 Family Proteins
To investigate the molecular action of vMAP, we tested
whether vMAP interacts with cellular apoptotic or anti-
apoptotic proteins of the Bcl-2 family. Co-immunoprecipita-
tion analyses showed that vMAP interacted with cellular Bcl-2
in transiently vMAP-expressing 293T cells and in cHV-68-
infected NIH3T3 cells (Figures 3A and S3A). In addition,
vMAP interaction with cellular Bcl-xL was readily detected in
cHV-68-infected NIH3T3 cells (Figure 3A). Despite the
equivalent expression of three different species of vMAP in
293T cells, the 16-kDa vMAP predominantly interacted with
Bcl-2, suggesting that the N-terminal sequence of vMAP is
likely required for Bcl-2 interaction (Figure S3A). To further
deﬁne the interaction between vMAP and Bcl-2 family
proteins, a mammalian GST fusion protein containing vMAP
(1–50) was coexpressed in 293T cells along with HA-tagged
Bcl-2, Bcl-xL,B a x ,B a k ,B i d ,o rB a d .v M A P ( 1 – 5 0 ) - G S T
efﬁciently interacted with Bcl-2 and Bcl-xL but not with
Bax, Bak, Bad, or Bid (Figure 3B and unpublished data).
However, vMAPD20-GST fusion lacking the N-terminal 20
amino acids completely lost its ability to bind to Bcl-2 and
Bcl-xL (Figure 3C). Interestingly, the N-terminal sequence
containing the ﬁrst 20 amino acids of vMAP is predicted to
adopt an amphipathic helical structure and share limited
similarity with the BH3 peptide of Bad (unpublished data).
However, deletion mutation analysis indicated that unlike the
BH3 peptide binding that requires the BH1, BH2, and BH3
domains of Bcl-2, the vMAP binding required the Bcl-2 85–
186-aa region containing the BH1 and BH3 domains only in
living cells (Figure S3B). This was further supported by the
results that Bcl-2 G145A mutation in the BH1 domain
abolished vMAP binding, whereas Bcl-2 W188A mutation in
the BH2 domain did not affect vMAP binding (Figure 3D). By
contrast, both mutations of Bcl-2 completely abrogated its
Bid-binding activity under the same conditions (Figure S3C).
This suggests that Bcl-2 binding to vMAP is different from its
binding to BH3-only proteins.
vMAP Interaction Facilitates Bcl-2 Mitochondrial
Localization
Bcl-2 family members are found in the cytoplasm, the
endoplasmic reticulum, and the nuclear membrane where
Figure 1. Genomic Localization and Protein Organization of cHV-68 vMAP
(A) vMAP is encoded within the ORF57. (Top diagram) The vMAP genomic localization is shown within the ORF57 sequence. Numbers indicate the
nucleotide position according to Entrez accession number U97553. The grid box represents a 90–base pair intron of ORF57 and the box with vertical
lines represents vMAP (M8). (Bottom diagram, sequence) The first ATG denotes the start codon for ORF57 (arrow on the left). The coding sequence of
vMAP is shown in reference to ORF57 and its amino acid sequence is listed below. The translation of vMAP has a þ1 shift to ORF57 frame; thus, the
vMAP amino acid sequence is completely different from the ORF57 amino acid sequence. The mitochondrion-targeting sequence (MTS) is italicized and
the putative transmembrane (TM) domain is indicated by bold letters. An arrow (#) over a gap (dots) indicates the splicing site where a 90–base pair of
intron is removed [47]. *, stop codon.
(B) vMAP protein organization. The N terminal sequence (aa 1–49) serves as a mitochondrial targeting sequence (MTS) as well as a Bcl-2-interacting
region. Both the internal hydrophobic region (aa 50–66) and the putative transmembrane (TM) domain (aa 135–157) interact with VDAC1.
doi:10.1371/journal.ppat.0030174.g001
PLoS Pathogens | www.plospathogens.org December 2007 | Volume 3 | Issue 12 | e174 1851
cHV-68 Anti-Apoptotic ProteinPLoS Pathogens | www.plospathogens.org December 2007 | Volume 3 | Issue 12 | e174 1852
cHV-68 Anti-Apoptotic Proteinthey act as sensors of cellular damage or stress. Upon stress,
members of Bcl-2 family proteins relocate to the mitochon-
drial surface where they exert their activity [6,18,19]. Thus,
mitochondrial recruitment of Bcl-2 is considered an impor-
tant step during the pro- or anti-apoptotic decision. To
examine whether vMAP interaction affected Bcl-2 intra-
cellular localization, the distribution of Bcl-2 was examined
by subcellular fractionation. Whole-cell lysates were sub-
jected to sequential centrifugation to obtain light membrane
(LM) fraction containing microsomes derived from the
endoplasmic reticulum or the trans Golgi network, HM
fraction enriched with mitochondria, and cytosolic fraction.
Densitometry quantiﬁcation of immunoblotting revealed that
approximately 70% and 30% of Bcl-2 was present in LM and
HM of NIH3T3/puro cells, respectively, whereas 30% and
70% of Bcl-2 was present in the LM and HM of NIH3T3/
vMAP cells, respectively (Figure 4A). vMAPD20 mutant that
failed to interact with Bcl-2 showed only a little effect on Bcl-
2 localization compared with wt vMAP (Figure 4A). It should
be noted that despite the 20-aa deletion at the N-terminus,
vMAPD20 mutant was still present primarily in the mito-
chondrion-enriched HM, as shown in Figures 4A and S2D,
suggesting that vMAP may contain at least two independent
motifs for its mitochondrial localization. To further test if
vMAP recruited Bcl-2 into the mitochondrion in vitro, HM
factions were used for mitochondrial association assay with
[
35S]-labeled Bcl-2 translated in rabbit reticulocyte lysates.
Bcl-2 mitochondrial association activity increased approx-
imately 2-fold in the HM fractions of NIH3T3/vMAP cells
compared with those of NIH3T3/puro cells (Figure 4B). These
results collectively indicate that vMAP actively recruits Bcl-2
to mitochondria, and that this vMAP activity requires the
speciﬁc interaction with Bcl-2.
vMAP Potentiates Bcl-2/Bcl-xL to Neutralize BH3-Only
Molecules
The ability to associate with BH3-only molecules correlates
with the anti-apoptotic activity of Bcl-2 and Bcl-xL [20,21].
Because vMAP facilitated the mitochondrial recruitment of
Bcl-2, we tested whether vMAP expression affected the ability
of Bcl-2 and Bcl-xL to associate with BH3-only molecules.
NIH3T3/puro and NIH3T3/vMAP cells were transfected with
Flag-tagged Bcl-2 and HA-tagged Bad or Bid. At 36 h post-
transfection, cell lysates were used for immunoprecipitation
with anti-HA, followed by immunoblotting with anti-Flag.
Surprisingly, the interaction of Bcl-2 with Bad or Bid was
considerably higher in NIH3T3/vMAP cells than in NIH3T3/
puro cells (Figure 5A and 5B). vMAP expression also had a
similar effect on the Bcl-xL-Bad interaction (Figure 5C). In
contrast, vMAP expression affected neither Bcl-2/Bcl-xL
interaction with Bax/Bak, nor Bcl-xL dimerization under the
same conditions (Figure S3D, S3E, and unpublished data).
vMAPD20, which failed to interact with Bcl-2 and Bcl-xL but
still localized at mitochondria, had no effect on their
interactions with Bid or Bad (Figure 5A and 5C, lane 4).
To further demonstrate the effect of vMAP on Bcl-2
interaction with BH3-only molecules in living cells, a ﬂow
cytometry–based ﬂuorescence resonance energy transfer
(FRET) assay was used to quantify the interaction between
Bcl-2 and Bid. NIH3T3/puro, NIH3T3/vMAP, and NIH3T3/
vMAPD20 cells were transfected with EYFP-Bcl-2 and ECFP-
Bid expression vectors. At 36 h post-transfection, these cells
were subjected to a FRET assay. The Bcl-2–Bid interaction
increased approximately 2- to 3-fold in NIH3T3/vMAP cells as
compared with NIH3T3/puro cells, whereas no signiﬁcant
difference was detected between NIH3T3/puro and NIH3T3/
vMAPD20 cells (Figure 5D). Furthermore, consistent with
immunoprecipitation results (Figure S3D and S3E), vMAP did
not signiﬁcantly alter the Bcl-2–Bax interaction in the FRET
assay (Figure S3F). These results demonstrate that vMAP
speciﬁcally facilitates the interactions of Bcl-2/Bcl-xL with
Bid/Bad.
vMAP Inhibits the Activation and Mitochondrial
Translocation of Bax
BH3-only pro-apoptotic proteins transduce death signals
from the cell surface or intracellular apoptotic pathways by
inducing a conformational change in Bax. Subsequently, Bax
translocates to mitochondria and oligomerizes within the
outer membrane, which ultimately leads to membrane
permeabilization and release of pro-apoptotic factors from
the intermembrane space [5,22]. To test if vMAP expression
affected Bax activation, mouse monoclonal antibody 6A7 that
speciﬁcally recognizes an epitope in the pro-apoptotic Bax
conformer was used to assess the level of Bax activation [23].
NIH3T3/puro and NIH3T3/vMAP cells were treated with ST
(1 lM) for 4 h, lysed with 1% CHAPS buffer, and subjected to
immunoprecipitation with the 6A7 monoclonal antibody or
the P-19 rabbit polyclonal antibody that reacts with total
Bax. NIH3T3/vMAP cells reproducibly showed lower levels of
the pro-apoptotic Bax conformer (Figure 6A). This difference
was not due to a reduced level of Bax expression, as
immunoprecipitation and immunoblotting with the P-19
antibody showed the equivalent amounts of Bax in both cells
Figure 2. cHV-68 vMAP Encodes a Mitochondrial Protein
(A) Identification of vMAP protein. (Left panel) cHV-68-infected (lane 2 and 3) or mock-infected NIH3T3 cells (lane 1) were harvested at 16 h post-
infection. Post-centrifuged lysates in CHAPS buffer were precipitated with pre-immune serum (lane 2) or anti-vMAP serum (lanes 1 and 3), followed by
immunoblotting (IB) with anti-vMAP serum. The arrowhead indicates vMAP. (Right panel) Subcellular fractionation of vMAP in 293T cells at 36 h post-
transfection, as shown by immunoblotting with antibodies to vMAP, COX4, or actin. W, whole cell lysate; C, cytosolic; HM, mitochondrion-enriched
heavy membrane.
(B) vMAP localizes to the mitochondrion. Post-transfection with pcDNA5-vMAP vector, COS-1 cells were stained with MitoTracker and fixed for anti-
vMAP immunostaining. The box inside of the right panel shows the merged image of MitoTracker and anti-vMAP immunostaining.
(C) Identification of the vMAP MTS. Either GFP alone or various vMAP N-terminal sequences fused to GFP were expressed in NIH3T3 cells. Mitochondria
were stained with anti–cytochrome c antibody (red). Pictures represent more than 85% of cells analyzed by fluorescent microscopy.
(D) vMAP inhibits apoptosis. NIH3T3/puro and NIH3T3/vMAP cells were treated with DMSO or ST (1 lM) for 16 h and stained with PI, followed by flow
cytometry analysis. Data are from one of three replicate experiments. vMAP (indicated by arrows) expression was shown by immunoblotting on the left.
(E) vMAP inhibits apoptosis initiated by various apoptogenic stimuli. NIH3T3/puro and NIH3T3/vMAP cells were treated with various agents (ST, TNF-a/
cycloheximide, vesicular stomatitis [VSV] infection for 16 h, or nocodazole [Noc] for 36 h), and sub-G1 cells were quantified as described in (D). Data
represent result of three independent experiments and error bars indicate standard deviation with (*) p , 0.05 relative to control (puro) as calculated by
Student’s t-test.
doi:10.1371/journal.ppat.0030174.g002
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showed that vMAP expression substantially suppressed the
ST-induced Bax activation in HeLa cells (Figure 6B). In
contrast, vMAPD20, which failed to interact with Bcl-2/Bcl-xL,
did not affect Bax activation (Figure 6B). Quantiﬁcation of
6A7 Bax antibody–positive cells showed that over 70% of
vMAPD20-expressing cells were positive to the 6A7 Bax
conformer antibody at 4 h after ST treatment, whereas only
25% of vMAP-expressing cells were positive (Figure 6B).
Subcellular fractionation was further used to examine the
mitochondrial translocation of Bax. NIH3T3/puro, NIH3T3/
vMAP, and NIH3T3/vMAPD20 cells were treated with ST (1
lM) for 4 h, and equivalent amounts of HM were used for
immunoblotting. Upon ST treatment, endogenous Bax
efﬁciently translocated into mitochondria in NIH3T3/puro
and NIH3T3/vMAPD20 cells, whereas a signiﬁcant reduction
of Bax mitochondrial translocation was detected in NIH3T3/
vMAP cells (Figure 6C). Equivalent amounts of Bax expression
were detected in all three cells (Figure 6C). Collectively, these
data indicate that vMAP expression signiﬁcantly suppresses
Bax activation as well as its mitochondrial translocation.
The Central and C-Terminal Hydrophobic Regions of
vMAP Interact with VDAC1
While the N-terminal 50 residues of vMAP were sufﬁcient
for interacting with Bcl-2 and this interaction exhibited a
Figure 3. vMAP Interacts with Bcl-2/Bcl-xL
(A) vMAP interacts with Bcl-2/Bcl-xL in cHV-68-infected cells. At 16 h post-infection, cHV-68-infected (MOI ¼ 1) or mock-infected NIH3T3 cells were
harvested and post-centrifuge supernatants were subjected to immunoprecipitation (IP) with rabbit antibodies to Bcl-2 or Bcl-xL, followed by
immunoblotting with anti-vMAP serum. A normal rabbit serum was included as a negative control. Protein precipitates were analyzed by
immunoblotting with antibodies to Bcl-2 and Bcl-xL (middle panel). Whole cell lysates (WCL) of mock-infected or cHV-68-infected NIH3T3 cells were
immunoblotted with anti-vMAP serum (bottom panel).
(B) The N-terminal sequence of vMAP interacts with Bcl-2/Bcl-xL but not with Bak and Bid. At 48 h post-transfection with a plasmid expressing HA-Bcl-2,
HA-Bcl-xL, HA-Bak, or HA-Bid, and a plasmid expressing GST (lane 2) or vMAP(1–50)-GST (lane 3), cell lysates of 293T were used for GST pull-down (PD)
assay, followed by immunoblotting with anti-HA (top panel of each set). WCLs were analyzed by immunoblotting with antibodies to HA epitope (Bcl-2
family proteins, middle panels) and GST (bottom panels) for GST or vMAP(1–50)-GST expression. Lane 1 is 2% input of lysates of cells expressing GST
and Bcl-2 family proteins. For all four sets of PDs (top panel), lane 1 shows the equivalent amount of Bcl-2 family proteins compared to those shown in
the middle panel.
(C) The first 20 amino acids of vMAP are essential for its interaction with Bcl-2/Bcl-xL. 293T cells were transfected with a plasmid expressing HA-Bcl-2, HA-
Bcl-xL together with a plasmid expressing GST (lane 1), vMAP-GST (lane 2), or vMAPD20-GST (lane 3). Mammalian GST pull-down was carried out as
described in (B). The precipitates were analyzed by immunoblotting with anti-HA to detect Bcl-2 and Bcl-xL (top two panels). WCLs were analyzed by
immunoblotting with anti-HA and anti-GST antibodies to demonstrate the expression of Bcl-2/Bcl-xL and GST fusion, respectively.
(D) The Bcl-2 BH2 domain is not involved in vMAP binding. At 48 h post-transfection with a plasmid expressing HA-Bcl-2, Bcl-2 G145A, or Bcl-2 W188A
together with a plasmid expressing GST (lane 2) or vMAP(1–50)-GST (lane 3), 293T cell lysates were used for GST pull-down, followed by
immunoblotting with Bcl-2 antibody (top panel of each set). WCLs were analyzed by immunoblotting with antibodies to Bcl-2 (middle panel) and GST
(bottom panel). Lane 1 indicates 2% input of lysates of cells expressing vMAP-GST and Bcl-2/Bcl-xL.
doi:10.1371/journal.ppat.0030174.g003
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interaction did not completely impede vMAP-mediated anti-
apoptosis (see below). This suggests that vMAP might have
additional cellular targets to achieve anti-apoptotic activity.
To test this idea, we used the yeast two-hybrid screen with
vMAP 50–157-aa region as bait to search for vMAP-interact-
ing cellular protein(s). This study identiﬁed cellular VDAC1
as a vMAP-interacting protein. An in vitro GST pull-down
experiment showed that vMAP speciﬁcally bound to cellular
VDAC1 (Figure 7A, right panel, lane 1).
vMAP contains two leucine-rich (LLxL, LIxL, and LxLV)
hydrophobic regions consisting of residues 50–66 and 135–
157 (Figure 7A, dark grey box). To test whether these
hydrophobic regions mediated the interaction with VDAC1,
bacterial GST-vMAP(50–157), GST-vMAP(66–135), GST-
vMAP(50–135), and GST-vMAP(66–157) fusion proteins were
used for in vitro GST pull-down assays, followed by
immunoblotting with antibody to VDAC1. GST fusions
containing either hydrophobic region 50–66 or 135–157
effectively interacted with endogenous VDAC1. GST alone or
GST-vMAP(66–135) did not interact with VDAC1 under the
same conditions (Figure 7A). Furthermore, the vMAP L/A
mutant carrying the replacement of the leucine and
isoleucine residues in both hydrophobic regions with alanines
no longer interacted with VDAC1 (Figure 7B). NIH3T3 cells
stably expressing wt vMAP, vMAPD20, or vMAP L/A at
equivalent levels (Figure S2E) were tested for vMAP and
VDAC1 interaction. Both vMAP wt and vMAPD20 efﬁciently
interacted with VDAC1, whereas vMAP L/A mutant did not
interact with VDAC1, indicating that the leucine-rich motifs
within the hydrophobic regions of vMAP are required for its
interaction with VDAC1 (Figure 7C). Finally, vMAP inter-
action with VDAC1 was readily detected in cHV-68-infected
NIH3T3 (Figure 7D).
Cellular VDAC1 is located at the mitochondrial outer
membrane and has a role in the release of pro-apoptotic
factors such as cytochrome c upon apoptotic stress [24]. To
test whether the vMAP–VDAC1 interaction affected cyto-
chrome c release, NIH3T3/puro and NIH3T3/vMAP cells were
treated with ST for 4 h and subjected to intracellular
fractionation, followed by immunoblotting with antibodies
to cytochrome c and COX4. This showed the signiﬁcant
release of mitochondrial cytochrome c to the cytosol in
NIH3T3/puro cells, whereas only minimal cytochrome c
leaked from mitochondria in NIH3T3/vMAP cells (Figure
7E). Finally, NIH3T3/vMAP L/A cells displayed considerable
release of mitochondrial cytochrome c upon ST treatment;
however, the extent of release was relatively lower in NIH3T3/
vMAP L/A cells than in NIH3T3/puro cells (Figure 7E). Taken
together, these results indicate that vMAP interacts with
mitochondrial outer membrane VDAC1 and that this
interaction robustly inhibits cytochrome c release.
Figure 4. vMAP Enhances the Mitochondrial Localization of Bcl-2
(A) Bcl-2 intracellular distribution by subcellular fractionation. NIH3T3/puro, NIH3T3/vMAP, and NIH3T3/vMAPD20 cells were transfected with HA-Bcl-2
expression vector. Twenty lg of WCL, cytosolic (Cyto), heavy membrane (HM), and light membrane (LM) fractions were analyzed by immunoblotting
with antibodies to HA epitope (HA-Bcl2, top panel), VDAC, tubulin, calreticulin (calret), or vMAP.
(B) In vitro Bcl-2 mitochondrial association assay. The mitochondrion-enriched HM fractions of NIH3T3/puro (lane 1) or NIH3T3/vMAP cells (lane 2) were
mixed with in vitro translated
35S-labeled Bcl-2 at 30 8C for 2 h, centrifuged at 13,000 rpm for 15 min to separate soluble (Super) and insoluble (Mito),
followed by autoradiograph. The left panel indicates Bcl-2 translated in rabbit reticulocyte lysates. The numbers below autography indicate the levels
(intensity of the Bcl-2 doublet) of mitochondrion-associated Bcl-2 determined by Phosphor Imager analysis.
doi:10.1371/journal.ppat.0030174.g004
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Apoptotic Activity
The biological signiﬁcance of the vMAP interactions with
Bcl-2/Bcl-xL and VDAC1 in anti-apoptosis was tested by
examining the effect of wt vMAP and its mutants (D20, L/A,
D20&L/A) on Bcl-2–Bid interaction, Bax translocation and
activation, cytochrome c release, and apoptosis (PI staining).
While vMAPD20 had no effect on the Bcl-2–Bid interaction
and Bax translocation/activation, the vMAP L/A mutant
potentiated the Bcl-2–Bid interaction and inhibited Bax
translocation/activation as efﬁciently as wt vMAP (Figure 8A–
8C). Functionally, vMAP activity to inhibit cytochrome c
release was detectably impaired by both mutations (D20 and
L/A), consistent with the ﬁnding that Bax permeabilizes the
mitochondrial outer membrane to release cytochrome c
(Figure 8D). These data indicate that vMAP targets two
mitochondrial apoptosis checkpoint proteins, Bcl-2/Bcl-xL
and VDAC1, in a genetically separable manner.
To further investigate the signiﬁcance of vMAP interac-
tions with Bcl-2 and VDAC1 in the inhibition of apoptosis,
NIH3T3 cells expressing wt vMAP or its mutants were treated
with ST for 16 h. ST treatment induced extensive apoptosis in
NIH3T3/puro cells, whereas wt vMAP efﬁciently blocked ST-
induced apoptosis (Figure 8E). In contrast, L/A and D20
Figure 5. vMAP Enhances the Interaction between Bcl-2/Bcl-xL and BH3-Only Proteins
(A–C) NIH3T3/puro cells (lane 2), NIH3T3/vMAP cells (lanes 1 and 3), and NIH3T3/vMAPD20 cells (lane 4) were transfected with plasmids expressing HA-
Bid and Flag-Bcl-2 (A), HA-Bad and Flag-Bcl-2 (B), or HA-Bad and Flag-Bcl-xL (C). WCLs were used for immunoprecipitation with a mouse monoclonal
anti-HA antibody, followed by immunoblotting with HRP-conjugated anti-Flag antibody to detect Flag-Bcl-2 and Flag-Bcl-xL (top panel) or with anti-HA
antibody to detect the precipitated HA-Bid and HA-Bad (second panels). WCLs were used to detect HA-Bid, HA-Bad, Flag-Bcl-2, and Flag-Bcl-xL
expression (bottom two panels) using antibodies to the HA epitope or Flag epitope. Lane 1 indicates anti-Myc immunoprecipitation of lysates from
NIH3T3/vMAP cells as a negative control. The light chains of the Myc and HA antibodies migrate differently on SDS-PAGE.
(D) Fluorescence resonance energy transfer (FRET) assay. At 36 h post-transfection with pEYFP-Bcl-2 and pECFP-Bid, NIH3T3/puro cells (Puro, panel 1),
NIH3T3/vMAPD20 cells (vMAPD20, panel 2), and NIH3T3/vMAP cells (vMAP, panel 3) were harvested and subjected to flow cytometry analysis. Numbers
in the FRET diagrams indicate the percentage of the transfected cell population without protein interaction (lower right) and the transfected cell
population with protein interaction (upper left). The right panel shows the data in the graph representing an average from two independent
experiments, and error bars indicate standard deviation with (*) p , 0.05 relative to control (Puro) as calculated by Student’s t-test.
doi:10.1371/journal.ppat.0030174.g005
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of vMAP under the same conditions (Figure 8E). Finally, the
D20&L/A double mutations completely abrogated the ability
of vMAP to inhibit ST-induced apoptosis (Figure 8E). These
results indicate that the Bcl-2 interaction displays a more
pronounced role in the vMAP-mediated anti-apoptosis than
the VDAC1 interaction, and both interactions lead to the
comprehensive inhibition of the mitochondrion-mediated
apoptosis.
vMAP Is Required for Efficient Lytic Replication of cHV-68
in Normal Fibroblasts but Not in Bax/Bak-Deficient
Fibroblasts
To investigate the effect of vMAP on cHV-68 lytic
replication, the bacterial artiﬁcial chromosome system was
used to generate recombinant cHV-68 DvMAP that contained
the removal of ﬁrst Met1 and second Met21 residues and the
insertion of a stop codon without affecting ORF57 coding
sequences (for details of nucleotide changes, please see
Materials and Methods). cHV-68 DvMAP Kan
R Bac was
initially constructed and subsequently used to generate
cHV-68 DvMAP and the revertant virus, called cHV-68 Rev,
which contained wt vMAP sequence (Figure S4A). vMAP
protein was readily detected in wt and revertant cHV-68-
infected cells but not in cHV-68 DvMAP-infected cells (Figure
S4B). To test if vMAP played a role in virus lytic replication,
wt cHV-68, cHV-68 DvMAP, and cHV-68 Rev were used to
infect NIH3T3, wt MEF, and Bax
 / Bak
 /  DKO MEF cells and
their replication kinetics were determined by plaque assay.
cHV-68 DvMAP replicated at levels that were 10- to 30-fold
Figure 6. vMAP Inhibits the Mitochondrial Translocation and Activation of Bax
(A) vMAP inhibits the apoptotic conformational change of Bax. NIH3T3/puro (Puro) and NIH3T3/vMAP (vMAP) cells were treated with ST (1 lM) for 4 h,
harvested, and lysed in 1% CHAPS buffer. Pre-cleared cell lysates were split into two fractions, and each was used for immunoprecipitation with the
mouse 6A7 monoclonal antibody or the rabbit P-19 polyclonal antibody, followed by immunoblotting with 6A7. WCLs were analyzed by
immunoblotting with 6A7 antibody. Of note, 6A7 antibody reacts only with the activated Bax in immunoprecipitation and immunofluorescence assays,
but with pan-bax in the immunoblotting assay. H and L indicate the heavy and light chains of immunoglobulin, respectively. WCL, whole cell lysate.
(B) vMAP inhibits Bax activation by immunofluorescence assay. At 16 h post-transfection with a plasmid expressing vMAP or vMAPD20, HeLa cells were
treated with DMSO or ST (1 lM) for 4 h, fixed, and stained with rabbit anti-vMAP serum (red) and the mouse 6A7 monoclonal anti-Bax antibody (green).
A single representative optical section is presented. Arrows indicate cells expressing vMAP or vMAPD20. The bottom right graph represents data
collected from over 200 transfected cells. Error bars indicate standard deviation with (*) p¼0.01 relative to vMAPD20 as calculated by Student’s t-test.
The bottom left panel shows the expression of vMAP and vMAPD20 (D20).
(C) vMAP inhibits Bax translocation by fractionation. NIH3T3/puro cells (Puro), NIH3T3/vMAP cells (vMAP), or NIH3T3/vMAPD20 cells (D20) were
untreated or treated with ST (1 lM) for 4 h, and the mitochondrion-enriched HM fractions (20 lg) were resolved by SDS-PAGE and analyzed by
immunoblotting with antibodies to detect endogenous Bax and COX4. WCLs were analyzed by immunoblotting with anti-Bax antibody (bottom panel).
doi:10.1371/journal.ppat.0030174.g006
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cycle than they were in wt cHV-68 and cHV-68 Rev (Figure
9A and 9B). However, this reduced replication capacity of
cHV-68 DvMAP was considerably diminished in Bax
 / Bak
 / 
DKO MEFs: cHV-68 DvMAP replicated at similar kinetic and
slightly reduced peak titer compared to wt cHV-68 (Figure
9B).
To further deﬁne the role of vMAP in mitochondrial cell
death during viral replication, mouse ﬁbroblast cells were
infected with wt cHV-68 or cHV-68 DvMAP, and Bax
activation was then examined by immunoprecipitation and
confocal microscopy with 6A7 Bax conformer antibody. After
treatment with ST (1 lM, 4 h), wt cHV-68-infected cells
showed the greatly reduced level of activated Bax compared
to mock-infected or cHV-68 DvMAP-infected cells (Figure 9C
and 9D). These results demonstrate that the vMAP gene is
required for efﬁcient cHV-68 lytic replication in normal
ﬁbroblast cells, but not in mitochondrial apoptosis-deﬁcient
Figure 7. vMAP Interaction with VDAC1 Inhibits Cytochrome c Release
(A) vMAP contains two VDAC1-interacting regions (dark grey boxes). The left panel shows the schematic diagram of vMAP interaction with VDAC1.
(Right panel) GST fusions containing various vMAP sequences were expressed and purified from E. coli. 293T cells were lysed in CHAPS buffer and
subjected to in vitro GST pull-down, followed by immunoblotting with anti-VDAC antibody. The bottom panel shows the Coomassie blue staining of
GST fusion proteins. Lanes 1–4 correspond to the GST fusions shown by the left diagram.
(B) The LLxL repeat sequences of vMAP are required for VDAC1 interaction. (Top box) The boxed sequences are the two LLxL repeats of vMAP. GST or
GST fusion proteins were used to bind to VDAC1 from 293T cell lysates in CHAPS buffer as described in (A). Protein precipitates were analyzed by
immunoblotting with anti-VDAC antibody (top blot) and Coomassie blue staining of GST fusion proteins (bottom blot).
(C) vMAP interacts with VDAC1 in stable cell lines. NIH3T3 cells stably expressing vector, vMAP, or its mutants were used for immunoprecipitation with
anti-vMAP serum or pre-immune (Pre) serum, followed by immunoblotting with anti-VDAC antibody (top panel) or anti-vMAP serum (middle panel).
WCLs were analyzed by immunoblotting with anti-vMAP serum and anti-VDAC antibody (bottom two panels).
(D) vMAP interacts with VDAC1 in cHV-68-infected cells. WCLs of mock (M)- or cHV-68 (c)-infected (MOI¼1) cells were precipitated with anti-vMAP or
preimmune serum, followed by immunoblotting with anti-VDAC antibody (top panel) or anti-vMAP serum (middle panel). WCLs were analyzed by
immunoblotting with anti-vMAP serum and anti-VDAC antibody (bottom two panels).
(E) vMAP inhibits cytochrome c release upon ST treatment. NIH3T3/puro, NIH3T3/vMAP, or NIH3T3/vMAP L/A cells were treated with ST (1 lM) for 4 h
and WCLs were sequentially centrifuged to obtain cytosolic (Cyto) and mitochondrion-enriched heavy membrane (HM) fractions. Polypeptides (20 lg)
from each fraction were analyzed by immunoblotting with antibodies to cytochrome c (Cyt C), COX4, and actin.
doi:10.1371/journal.ppat.0030174.g007
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role in cHV-68 lytic replication by inhibiting the premature
mitochondrial apoptotic death of host cells during acute
replication, allowing completion of viral replication cycle.
Discussion
Here, we report the identiﬁcation of a novel mitochondrial
anti-apoptotic vMAP of cHV-68, of which its N-terminal MTS
is sufﬁcient for the mitochondrial localization. vMAP
interacts with Bcl-2 and increases Bcl-2 mitochondrial local-
ization, leading to the neutralization of BH3-only pro-
apoptotic molecules. Additionally, vMAP binds to the
mitochondrial VDAC1 through its internal and C-terminal
hydrophobic sequences, thereby inhibiting cytochrome c
release upon apoptotic stresses. Taken together, these data
indicate that vMAP engages cellular Bcl-2 and VDAC
apoptosis checkpoint proteins to comprehensively inhibit
Figure 8. vMAP Interacts with Bcl-2 and VDAC1 in a Genetically Separable Manner
(A) vMAP interaction with Bcl-2, but not with VDAC1, enhances Bcl-2 binding to Bid. NIH3T3 stable cells expressing puro (lane 2), vMAP (lanes 1 and 3),
vMAPD20 (lane 4), or vMAP L/A (lane 5) were transfected with plasmids containing Flag-Bcl-2 and HA-Bid. At 48 h post-transfection, cells were harvested
and WCLs were used for immunoprecipitation with anti-HA (Bid), followed by immunoblotting with HRP-conjugated anti-Flag (Bcl-2, top panel) or anti-
HA antibody (middle panel). WCLs were analyzed by immunoblotting with anti-HA (Bid) and anti-Flag (Bcl-2) antibodies (bottom two panels). Anti-Myc
antibody in lane 1 was included as a negative control.
(B) vMAP-Bcl-2 interaction but not vMAP-VDAC1 interaction is required to inhibit Bax mitochondrial translocation. NIH3T3 stable cells were treated with
ST (1 lM) for 4 h, and mitochondrion-enriched HMs (20 lg) were analyzed by immunoblotting with anti-Bax or anti-VDAC antibody (top two panels).
WCLs were used for immunoblotting with anti-Bax (bottom panel). Lane 1, NIH3T3/puro; lane 2, NIH3T3/vMAP; lane 3, NIH3T3/vMAPD20; lane 4,
NIH3T3/vMAP L/A; lane 5, NIH3T3/vMAPD20&L/A.
(C) vMAP-Bcl-2 interaction but not vMAP-VDAC1 interaction is required to inhibit the mitochondrial translocation of Bax. NIH3T3 cells expressing wt
vMAP or mutants thereof were stimulated with ST (1 lM) for 4 h. WCLs were precipitated with anti-Bax P-19 polyclonal antibody or 6A7 monoclonal
antibody, followed by immunoblotting with 6A7 monoclonal antibody as described in Figure 6A. The content of the lanes is same as described in (B). H
and L indicate the heavy and light chains of immunoglobulin, respectively.
(D) vMAP interactions with Bcl-2 and VDAC1 are required to efficiently inhibit cytochrome c release. NIH3T3 cells containing vector (P), vMAP, vMAPD20
(D20), or vMAP L/A (L/A) were treated with ST (1 lM) for 4 h. Mitochondrion-enriched HM and cytosolic fractions (Cytosol) were obtained by
centrifugation as described in Materials and Methods. Each fraction (20 lg) was resolved by SDS-PAGE and analyzed by immunoblotting with
antibodies to cytochrome c (Cyt C), COX4, and tubulin (cytosolic fraction only).
(E) Roles of vMAP interactions with Bcl-2 and VDAC1 in anti-apoptosis. NIH3T3 cells were treated with ST (1 lM) for 16 h and subsequently stained with
PI for flow cytometry. Data represent three independent experiments. Error bars indicate standard deviation with (*) p , 0.05 relative to control
(NIH3T3/puro cells, 1) as calculated by Student’s t-test. The content of the lanes is same as described in (B).
doi:10.1371/journal.ppat.0030174.g008
PLoS Pathogens | www.plospathogens.org December 2007 | Volume 3 | Issue 12 | e174 1859
cHV-68 Anti-Apoptotic Proteinthe mitochondrion-mediated intracellular innate immunity,
which allows completion of efﬁcient viral lytic replication
(Figure 9E).
Previous functional studies have classiﬁed BH3-only pro-
teins as either death agonists such as Bid and Bim or survival
antagonists like Bad [22,25]. Recently, this has been formally
proposed as the ‘‘hierarchy model’’, which postulates that the
survival antagonist mainly promotes apoptosis by neutraliz-
ing anti-apoptotic Bcl-2 members, the death agonist induces a
conformational change, oligomerization, and activation of
Bax/Bak through a ‘‘hit-and-run’’ mechanism, thereby ampli-
fying apoptotic signaling with a limited amount of cleaved
Bid or dephosphorylated Bim [26]. In normal cells, the death
agonist is held in check by anti-apoptotic Bcl-2 family
proteins. When apoptosis is triggered, the survival antagonist
binds to anti-apoptotic Bcl-2 proteins that release the death
agonist, which subsequently activates Bax or Bak. This model
places the survival antagonist upstream of the death agonist.
Figure 9. vMAP Anti-Apoptotic Activity Is Required for the Efficient Replication of cHV-68
(A) vMAP is required for the efficient replication of cHV-68 in NIH3T3 cells. NIH3T3 cells were infected with cHV-68 wt, cHV-68 DvMAP, or cHV-68 Rev at
MOI¼0.01 (solid line) or MOI¼5 (dashed line). Culture (cells and supernatants) was harvested at various time points post-infection. Plaque assay was
performed with BHK21 cells. Data represent duplicate experiments and error bars indicate standard deviation with (*) p , 0.07 relative to cHV-68
DvMAP as calculated by Student’s t-test. dpi, days post infection. The p-value can be applied for both cHV-68 wt and cHV-68 Rev.
(B) vMAP is dispensable for cHV-68 replication in Bax
 / Bak
 /  (DKO) MEF. wt or Bax
 / Bak
 /  (DKO) MEF cells were infected with cHV-68 wt or cHV-68
DvMAP at MOI ¼ 1. Culture (cells and supernatants) was harvested at various time points post infection. Solid lines and dashed lines indicate growth
kinetics of cHV-68 in wt MEFs and DKO MEFs, respectively. Data represent the results of two independent measurements and error bars indicate
standard deviation with (*) p , 0.06 relative to wt MEF as calculated by Student’s t-test.
(C and D) vMAP expression inhibits Bax activation during cHV-68 replication. NIH3T12 cells were mock-infected (Mock), infected with cHV-68 wt (Wt) or
cHV-68 DvMAP (DvMAP) at MOI ¼ 2 for 12 h, and then untreated or treated with ST at 1 lM for 4 h. Bax activation was examined by
immunoprecipitation (P-19 and 6A7) and immunoblotting (6A7) (C) or confocal microscopy with 6A7 monoclonal antibody (D) as described in Figure 5.
Numbers in (D) indicate the percentages of 6A7 Bax conformer positive cells.
(E) A hypothetical model of vMAP action in the inhibition of mitochondrion-mediated apoptosis. cHV-68 vMAP recruits Bcl-2 to the mitochondrion and
enhances Bcl-2 interaction with BH3-only proteins, thereby blocking Bax translocation and activation. On the other hand, vMAP interactions with both
Bcl-2 and VDAC1 lead to a comprehensive inhibition of cytochrome c release upon apoptotic stress. Red-colored lines indicate vMAP-mediated
inhibition.
doi:10.1371/journal.ppat.0030174.g009
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activating Bax/Bak and inducing apoptosis [22,25]. Our data
is in support of the hierarchy model regarding the action of
BH3-only molecules. Conceivably, vMAP interaction may
activate Bcl-2/Bcl-xL to adopt their anti-apoptotic conforma-
tion, effectively neutralizing the pro-apoptotic BH3-only
molecules through a direct interaction, which ultimately
blocks Bax activation. It has been shown that cellular orphan
nuclear receptor Nur77 has an activity to modulate Bcl-2
conformation and convert Bcl-2 into a pro-apoptotic
molecule [27]. This suggests that vMAP may resemble Nur77
by altering cellular Bcl-2/Bcl-xL conformation, but this
activity transforms Bcl-2 into an anti-apoptotic conformation
rather than a pro-apoptotic form. However, it should be
noted that the vMAP exhibits no speciﬁcity in Bcl-2
interactions with the death agonist Bid or the survival
antagonist Bad. It is possible that vMAP increases the pool
of activated anti-apoptotic Bcl-2 in general, which is reﬂected
by the elevated interaction with Bid as well as Bad. In
contradiction to the hierarchy model, BH3-only molecules
have recently been proposed to induce apoptosis primarily
through neutralization of Bcl-2 anti-apoptotic proteins, but
not through activation of Bax/Bak [28]. The reason for this
seemingly discrepancy between these two models is not clear
and may be derived from various different mutant proteins
and functional tests that each study relied on [26,28]. Thus,
further studies are required to resolve this issue regarding
BH3-only molecules. Nevertheless, our data indicate that the
vMAP facilitates the interactions of Bcl-2/Bcl-xL with Bid/Bad
BH3-only molecules, which neutralizes Bid/Bad pro-apoptotic
activity, inhibits Bax activation, and thereby likely raises the
threshold for cells to execute apoptosis.
In addition to Bax/Bak activation, the PTP complex
represents an additional apoptotic checkpoint within the
mitochondrial membrane. Along with accessory components,
the PTP complex is mainly composed of ANT and VDAC that
connect the mitochondrial outer membrane with its inner
membrane at contact sites. Although ANT and VDAC may
not be required for mitochondrion permeabilization, accu-
mulating data indicate that they are implicated in releasing
pro-apoptotic factors from the intermembrane space
[7,24,29,30]. Cellular Bcl-2 family proteins and viral polypep-
tides differentially modulate the PTP complex through a
direct interaction with ANT, VDAC, or their accessory
components, and therefore regulate apoptosis [7,31–33].
Our present study adds vMAP to the expanding family of
proteins that inﬂuence the permeability transition by virtue
of protein–protein interactions. The two vMAP LLxL repeats
independently mediate an interaction with VDAC1 that is
required to efﬁciently inhibit cytochrome c release, an
indication of the mitochondrial permeability transition.
We have deﬁned two functional domains within vMAP: the
N-terminal Bcl-2-binding domain and the central/C-terminal
VDAC1 interaction domain. It is reasonable to speculate the
potential presence of a ternary complex consisting of vMAP,
Bcl-2, and VDAC1. Given that Bcl-2 physically and function-
ally interacts with VDAC1 [7], the introduction of vMAP to
this complex may inﬂuence the Bcl-2/VDAC1 interaction if a
ternary complex is present. However, we observed no
detectable effect of vMAP on the interaction between Bcl-2
and VDAC1 (Figure S5). On the other hand, it is also possible
that vMAP independently binds to cellular Bcl-2 or VDAC1.
Consistent with this, the aforementioned two binding
domains of vMAP are genetically separable in that mutations
within each domain only affect its corresponding interaction,
leaving the other interaction intact. Alternatively, the
formation of a ternary complex may be dependent on the
integrity of a lipid bilayer. Therefore, additional approaches
other than traditional immunoprecipitation are required to
assess vMAP interactions with Bcl-2 and VDAC1.
While both Bcl-2 and VDAC1 interactions are essential for
vMAP-mediated inhibition of apoptosis, Bcl-2 binding seems
to be more functionally important in vMAP-mediated
inhibition of apoptosis than that of VDAC1. This is consistent
with the ﬁndings that Bax and Bak are the essential players
that open the mitochondrial gate to the cell death program
[6,9]. In addition, Bcl-2 family proteins are also important in
regulating cytochrome c release during apoptosis. Indeed,
vMAPD20 that no longer bound to Bcl-2 partially lost its
activity to inhibit cytochrome c release (Figure 8C). While
vMAP L/A mutant that no longer bound to VDAC1
signiﬁcantly failed to block cytochrome c release, a detectable
amount of cytochrome c was still retained in the mitochond-
rion in these cells (Figure 7E). These data support the idea
that vMAP interaction with Bcl-2 also plays a role in the
inhibition of cytochrome c release. Taken together, these
results indicate that vMAP interactions with both Bcl-2 and
VDAC1 synergistically contribute to its inhibition on the
mitochondrion-mediated apoptosis.
The N-terminal MTS of vMAP entirely overlaps with its
Bcl-2 binding motif. This suggests that the N-terminal
deletion mutation, vMAPD20, may ablate two functions of
vMAP simultaneously: Bcl-2 binding and mitochondrial
targeting. However, the results of cell fractionation and
confocal microscopy showed that the majority of vMAPD20
still localized to the mitochondrion (Figures 4A and S2D).
This indicates that vMAPD20 mutation ablates only the Bcl-2
binding activity without signiﬁcantly affecting vMAP mito-
chondrial localization. This also suggests the presence of
additional mitochondrial targeting sequence. Unfortunately,
our GFP fusion strategy failed to identify additional linear
sequence for its mitochondrial localization (unpublished
data). This implies that, perhaps, a higher order of structure
of vMAP may be required to function as an MTS as seen with
VDAC [34]. The cleavable N-terminal MTS generally sends
protein into the matrix or interior membrane of mitochon-
dria, while the uncleavable N-terminal MTS targets protein
into the outer membrane of mitochondria [35]. In fact, vMAP
N-terminal MTS appeared to be not cleaved based on its
molecular weight in SDS-PAGE (Figures 2A and 4A). Addi-
tionally, a mutation at the potential mitochondrial signal
peptide cleavage site of vMAP did not affect its mitochondrial
localization (unpublished data). These results collectively
suggest that an alternative MTS exists in addition to the N-
terminal MTS.
The expression proﬁle and function activity of cHV-68
vMAP has unique features. First, vMAP is present within the
second exon of the ORF57 transcript, which encodes an
immediate early gene product that is essential for viral
replication, a homolog of herpes simplex virus ICP27 [17,36].
This suggests that the vMAP gene has co-evolved with ORF57
and likely plays a critical role in cHV-68 replication. Second,
the putative N-terminal amphipathic a-helical region of
vMAP has both mitochondrial targeting and Bcl-2-binding
PLoS Pathogens | www.plospathogens.org December 2007 | Volume 3 | Issue 12 | e174 1861
cHV-68 Anti-Apoptotic Proteinactivities. Of note, the vMAP contains an unidentiﬁed MTS,
in addition to its N-terminal MTS, that potentially targets
vMAP to the outer membrane of mitochondria. Finally, vMAP
targets two mitochondrial proteins, Bcl-2 and VDAC1, to
affect a comprehensive inhibition of the mitochondrion-
dependent apoptosis. Interestingly, human cytomegalovirus
(HCMV) vMIA uses a similar strategy to deregulate mito-
chondrion-dependent apoptosis: vMIA neutralizes and inhib-
its permeability transition pore activity through its direct
interactions with Bax [32,37,38]. Intriguingly, vMIA is also
encoded within the ﬁrst exon of UL37 of HCMV, an
immediate early gene transcript that is required for viral
replication [39,40]. However, inactivating the vMIA expres-
sion by mutagenesis did not dramatically reduce HCMV lytic
replication, similar to what we reported here for vMAP
deletion for cHV-68 lytic replication in tissue culture [41].
Thus, it is surprising that these viruses have undergone
convergent evolution, evolving independently to encode
mitochondrial proteins with similar molecular mechanisms
but without discernable sequence similarity.
Materials and Methods
Cells, virus, and plaque assays. NIH3T3, NIH3T12, BHK21, COS-1,
and 293T cells were grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 100 U/ml streptomycin and penicillin. BJAB and S11 cells
were grown in RPMI 1640 supplemented with 10% fetal bovine
serum, L-glutamine, and antibiotics. Fugene 6 (Roche), lipofectamine
(Invitrogen), or calcium phosphate (Clontech) was used for transient
expression of vMAP in COS-1, NIH3T3, and 293T cells. NIH3T3
stable cell lines were established using a standard protocol of
puromycin selection at 2 lg/ml. wt MEFs or Bax
 / Bak
 /  DKO MEFs
t r a n s f o r m e dw i t hS V 4 0w e r eg e n e r o u s l yp r o v i d e db yS t a n l e y
Korsmeyer (Dana-Farber Cancer Institute, Harvard Medical School)
and grown in complete DMEM medium.
cHV-68 wt and GFP viruses were ampliﬁed in NIH3T12 cells. After
three rounds of freeze-thawing, supernatants of virus-infected cells
were used for de novo infection of BHK21 or NIH3T12 cells. Plaque
assays were performed in BHK21 cells overlaid with 1% methyl-
cellulose as described previously [42].
cHV-68 recombinant virus. cHV-68DK3-GFP was kindly provided
by Dr. Philip Stevenson. To generate vMAP deletion recombinant
virus, the bacterial artiﬁcial chromosome [43] containing the entire
cHV-68 genome was used. Due to the fact that the vMAP coding
sequence overlaps with ORF57, we generated cHV-68 DvMAP by
changing the ﬁrst and second initiation codons of vMAP to AAG and
introducing two stop codons (T . A changes at nucleotide positions
of 76016, 76049, 76076, and a G . A change at nucleotide position of
76079 based on Entrez accession number U97553). These changes did
not affect the ORF57 coding sequence. Initially, the vMAP coding
sequence was replaced with a KanR/LacZ cassette (cHV-68 Bac DvMAP
Kan
R) by allelic exchange [42] (Figure S4A). Since ORF57 was
required for cHV-68 replication, vMAP sequences containing various
mutations were ampliﬁed by PCR and electroporated into BHK21
cells together with cHV-68 Bac DvMAP Kan
R DNA to allow
homologous recombination. Viruses obtained from BHK21 cells,
cHV-68 DvMAP or cHV-68 Rev, were plaque puriﬁed and further
ampliﬁed in BHK21 cells (Figure S4A). Virion DNAs were used for
PCR ampliﬁcation to clone ORF57 and vMAP DNA fragments,
followed by DNA sequence to conﬁrm the presence of designed
changes and the absence of aberrant changes. Virion DNA was also
digested with BamHI or BglII to exclude the possibility of viral
genomic rearrangement (Figure S4C). Viruses were then used to
infect NIH3T3 or BHK21 cells to determine replication kinetics.
Antibody production. His-tagged vMAP (1–135) was puriﬁed from
E. coli strain BL21 using Ni-conjugated agarose according to
manufacturer’s instructions (Qiagen). Urea was removed using
Centricon (Millipore), after which protein concentration was
measured with the Bradford method (Bio-Rad). Polyclonal antibodies
against His-tagged vMAP (1–135) were produced in two rabbits.
Plasmids. Unless speciﬁed, all constructs were derived from
pcDNA5/FRT/TO (Invitrogen) or pEF-IRES-puro [44]. A DNA frag-
ment corresponding to the cHV-68 vMAP coding sequence was
ampliﬁed from S11 genomic DNA by PCR and cloned into pcDNA5/
FRT/TO between BamHI and XhoI. To generate GFP fusion proteins,
vMAP or vMAP (1–49) and its derivatives were PCR ampliﬁed and
ligated to pEGFPN1 digested with BglII and SalI. Mutations in the
vMAP gene were generated by PCR using oligonucleotide-directed
mutagenesis. All constructs were sequenced with an ABI PRISM 377
automatic DNA Sequenzer. Constructs expressing the HA-tagged and
GFP-tagged Bcl-2 family proteins were kindly provided by J. Marie
Hardwick (John Hopkins University), Beth Levine (UT-Southwestern
Medical Center), and Richard J. Youle (National Institutes of Health),
respectively. HA-Bcl-xL and Flag-Bax were ampliﬁed by two-step PCR
using GFP-Bcl-xL and GFP-Bax as templates and cloned into pcDNA5/
FRT/TO between the BamHI and XhoI sites. Bcl-2 was cloned into
pEYFP-C1 at the BamHI site, and Bax and Bid were cloned into
pECFP-C1 between the BamHI/XhoI sites, respectively. To produce
His-tagged vMAP protein from E. coli, vMAP (1–135) was PCR
ampliﬁed and cloned into pQE40 (Qiagen). To express GST fusion
proteins in mammalian cells, vMAP sequences were PCR ampliﬁed
and cloned into pDEF3 digested with KpnI and EcoRV.
Immunoblotting and immunoprecipitation. For immunoblotting,
polypeptides were resolved by SDS-PAGE and transferred to PVDF
membranes (Bio-Rad). Immunoblot detection was performed with
anti-V5 (1:5000; Invitrogen), M2 anti-Flag (1:5000; Sigma), anti-GST
(1:2000; Santa Cruz Biotechnology), anti-VDAC (porin 31HL) (1:1000;
CALBIOCHEM), anti-Bax (6A7, 1:1000, Pharmingen), anti-COX4
(1:100; Clontech), anti-Bcl-2 (1:100, Santa Cruz Biotechnology), anti-
Bcl-xL (1:100, Pharmingen), or anti–cytochrome c (1:200, Clontech;
1:1000, Pharmingen). Rabbit anti-vMAP serum was diluted 1:3000 for
immunoblots. Proteins were visualized using a chemiluminescence
detection reagent (Pierce) and quantiﬁed using a Fuji Phosphor
Imager.
For immunoprecipitation, cells were harvested and then lysed with
1% CHAPS buffer (Cell Signaling) supplemented with 1 mM
dithiothreitol (DTT) and protease inhibitor cocktail (Roche). After
pre-clearing with protein A/G–agarose beads for 1 h at 4 8C, whole-
cell lysates were used for immunoprecipitation. Generally, 1–4 lgo f
commercial antibody or 1 ll of vMAP antiserum was added to 1 ml
cell lysate, which was incubated at 4 8C for 8 to 12 h. After addition of
protein A/G–agarose beads, the incubation was further extended for 1
h. The beads were extensively washed with lysis buffer, and the
immunoprotein precipitates were eluted with SDS loading buffer by
boiling for 5 min.
Immunoﬂuorescence microscopy. Sixteen hours after transfection
or electroporation, cells were ﬁxed with 4% paraformaldehyde for 15
min, permeabilized with 0.2% (v/v) triton X-100 for 15 min, blocked
with 10% goat serum in PBS for 30 min, and reacted with diluted
primary antibody in PBS for up to 2 h at room temperature. After
incubation, cells were washed extensively with PBS, incubated with
the appropriate secondary antibody diluted in PBS for 30 min at
room temperature, and washed three times with PBS. Mitochondrial
staining was performed with 250 nM MitoTracker (Molecular Probes)
for 20 min followed by washing with PBS at room temperature for 5
min. Alternatively, mitochondria were visualized using antibodies
against mitochondrial proteins including cytochrome c and HSP60.
Confocal microscopy was performed using a Leica TCS SP laser-
scanning microscope (Leica Microsystems) ﬁtted with a 1003 Leica
objective (PL APO, 1.4NA) and Leica imaging software. Images were
collected at 512 3 512-pixel resolution. The stained cells were
optically sectioned in the z-axis, and the images in the different
channels (photo multiplier tubes) were collected simultaneously. The
step size in the z-axis varied from 0.2 to 0.5 lm to obtain 16 slices per
imaged ﬁle. The images were transferred to a Macintosh G4 computer
(Apple Computer) and Photoshop (Adobe) was used to render the
images.
For immunoﬂuorescence microscopy, antibodies were directed
against cytochrome c (1:200), Bax 6A7 (1:100; Pharmingen), HSP60
(1:100; Santa Cruz Biotechnology), vMAP (1:100), V5 (1:100; Invitro-
gen), or VDAC 31HL (1:100; CALBIOCHEM). All conjugated
secondary antibodies were obtained from Molecular Probes and
diluted at 1:1000 or 1:500. These included Alexa 488–conjugated goat
anti–rabbit IgG, Alexa 568–conjugated goat anti–mouse IgG, Alexa
488–conjugated goat anti–mouse IgG, Alexa 594–conjugated donkey
anti–goat IgG, Alexa 488–conjugated donkey anti–rabbit IgG, and
Alexa 594–conjugated donkey anti–mouse IgG.
GST pull-down. In vitro GST pull-down was similar as previously
described [45]. Brieﬂy, E. coli (BL21) cells were induced with IPTG (1
lM) for 2 h and lysed with PBS containing 0.1% sarcosyl. GST or GST
fusions were puriﬁed with glutathione-conjugated Sepharose beads
and either used for immediate experiments or stored at  20 8C for
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glutathione-conjugated Sepharose and binding was extended at 4 8C
for up to 2 h. After extensive washing, protein precipitates were
resolved by SDS-PAGE and transferred to PVDF membrane, followed
by immunoblotting.
For mammalian GST pull-down, 293T cells expressing GST fusion
proteins and Bcl-2 family proteins were harvested and lysed with 1%
CHAPS buffer (50 mM HEPES [pH 7.4]; 100 mM NaCl; 10 mM Tris; 1
mM EDTA; 1% CHAPS) supplemented with protease inhibitor
cocktail (Roche). Supernatants after centrifugation procedures were
pre-cleared with 15 ll of protein A/G beads at 4 8C for 1 h, after which
40 ll of 50% glutathione-conjugated Sepharose beads was added and
binding was extended for 2 to 3 h at 4 8C. Protein precipitates were
washed extensively with lysis buffer and analyzed by immunoblotting.
Yeast two-hybrid screen. The yeast two-hybrid screen was
performed as previously described [45,46]. Yeast strain AH109
bearing the Gal4-vMAP (50–157) fusion gene plasmid was used to
screen a cDNA library generated from EBV-immortalized B cells.
Mitochondrial enrichment. To obtain the mitochondrion-enriched
HM fraction, 293T or NIH3T3 cells were harvested and washed with
ice-cold PBS and resuspended with hypotonic buffer (10 mM Tris;
250 lM sucrose; 20 mM HEPES [pH 7.4]; 0.2 mM EDTA) supple-
mented with 1 mM DTT and protease inhibitor cocktail. The
suspension was incubated on ice for 15 min and lysed with Nitrogen
Bomber (Parr Instrument Company) at 250 psi for 15 min. Nuclei and
unbroken cells were removed by centrifugation at 700g for 10 min.
The supernatant at this point was regarded as whole cell lysate and
was subjected to centrifugation at 6,000g for 15 min. The pellet was
then resuspended with hypotonic buffer and centrifuged at 6,000g for
15 min; this process was repeated twice to obtain the mitochondrion-
enriched fraction. The supernatant was further centrifuged at
100,000g for 90 min to yield the cytosolic fraction (supernatant),
and the pellet was collected and regarded as the light membrane
fraction. When cytochrome c release was examined, the step to obtain
light membranes was skipped.
Apoptosis assay. Stably transfected NIH3T3 cells were grown in
complete DMEM with 2 lg/ml puromycin. Cells, 1310
6 per well, were
used for apoptosis induction with 1 lM ST for up to 16 h. After
treatment, cells were harvested with cell dissociation buffer (Sigma)
and ﬁxed with 70% ethanol overnight. After staining the cells with PI
for 30 min at room temperature, DNA content was measured with
ﬂow cytometry and analyzed with CellQuest (BD Biosciences).
Alternatively, cells were treated with other apoptogenic agents
(TNF-a plus cycloheximide, VESICULAR STOMATITIS infection,
nocodazole), and sub-G1 cells were measured as described above.
For cytochrome c release, NIH3T3 cells were induced with 1 lMo f
ST for 4 h and harvested. The mitochondrion-enriched fraction was
obtained as described above. Cytochrome c and mitochondrial
membrane marker COX4 were detected by immunoblotting using
the antibody from the ApoAlert kit (Clontech). For Bax mitochon-
drial translocation, cells were stimulated with 1 lM ST for 4 h and
processed for intracellular fractionation as described above. For Bax
activation, cells were stimulated with 1 lM ST for 4 h, and whole-cell
lysates in 1% CHAPS buffer were precipitated with the mouse 6A7
monoclonal antibody or the rabbit P-19 polyclonal antibody, and
protein precipitates were analyzed by immunoblotting.
For cHV-68DK3-GFP infection in wt and Bax
 / Bak
 /  DKO MEF
cells, the activated caspase 3 was measured by intracellular staining
according to manufacturer’s instruction (BD Pharmingen), followed
by ﬂow cytometry analysis. Meanwhile, dead cells were stained with
trypan blue and counted under light microscope.
In vitro mitochondrion recruitment of Bcl-2. Bcl-2 was in vitro
translated from TNT-coupled reticulocyte lysate systems (Promega)
and labeled with [
35S]-methionine/cysteine. The mitochondrion-
enriched HM fraction was obtained as described above from
NIH3T3/puro or NIH3T3/vMAP cells. Protein was measured with
the Bradford method and 50 lg of mitochondrial proteins were
mixed with 100 ll of reticulocyte lysates containing the radioactively
labeled Bcl-2. The mixtures were incubated at 30 8C for 2 h and
mitochondria were pelleted at 13,000 rpm for 15 min. While the
supernatants were collected as membrane-free Bcl-2, the pellets were
washed twice with hypotonic buffer and resuspended in PBS as
mitochondrion-associated Bcl-2. Proteins were then analyzed by
gradient (4%–12%) SDS-PAGE and Phosphor Image reader.
Fluoresence resonance energy transfer (FRET) assay. NIH3T3/vec,
NIH3T3/vMAP, and NIH3T3/vMAPD20 were transfected with pEYFP-
Bcl-2 and pECFP-Bid. At 36 h post-transfection, cells were harvested
with dissociation buffer and washed twice with room temperature
PBS containing 0.5% bovine serum albumin. Next, cells were
subjected to ﬂow cytometry that is equipped with ﬂuorochrome
excitation capability.
Supporting Information
Figure S1. The Mitochondrion-Dependent Apoptosis Limits cHV-68
Replication
(A) cHV-68 replication in wild-type (wt) or Bax
 / Bak
 /  (DKO) MEFs.
wt or DKO MEFs were infected with cHV-68DK3-GFP at a multi-
plicity of infection (MOI) of 1, and subsequently photographed at
post-infection day 1 (103) and day 2 (43 objective).
(B) Replication kinetics of cHV-68DK3-GFP. wt and DKO MEFs were
infected with cHV-68DK3-GFP at an MOI of 1. Cells and supernatants
were harvested at various time points. Virus titer was determined by
plaque assay in BHK21 cells. Data represent the result of four
independent measurements and error bars indicate standard devia-
tion with (*) p , 0.05 relative to wt MEF cells as calculated by
Student’s t-test.
(C) Intracellular activated caspase 3 staining. wt or DKO MEFs were
infected with cHV-68DK3-GFP and subsequently harvested at various
time points. Cells were stained with PE-conjugated antibody that is
speciﬁc for the activated caspase 3 and analyzed by ﬂow cytometry.
Data represent one of two independent experiments.
(D) Trypan blue staining upon cHV-68DK3-GFP infection. Viral
infection was carried out as described in (C). wt or DKO MEFs were
harvested at day 3 post-infection and stained with trypan blue. Data
represent the average of two independent experiments and error
bars indicate standard deviation with (*) p ¼ 0.02 relative to wt MEF
cells as calculated by Student’s t-test.
Found at doi:10.1371/journal.ppat.0030174.sg001 (428 KB TIF).
Figure S2. Mitochondrial Localization of vMAP
(A) The reactivity of anti-vMAP serum. COS-1 cells expressing vMAP-
V5 were ﬁxed and stained with rabbit pre-immune serum or anti-
vMAP serum. A single representative optical section is presented.
(B) The mitochondrial localization of vMAP-GFP fusion protein by
subcellular fractionation. NIH3T3 cells were transiently transfected
with pEGFP-N1 plasmid or its derivatives containing vMAP (1–40) or
vMAP (1–30). At 36 h post-transfection, cells were harvested and
subjected to fractionation. Twenty lg of proteins were analyzed by
immunoblotting to detect GFP fusion proteins with a rabbit anti-GFP
antibody (top two panels). Immunoblotting with anti-COX4 and anti-
actin antibodies were included as controls (bottom two panels). WCL,
whole-cell lysate; HM, mitochondrion-enriched heavy membrane;
Cyto, cytosolic fraction.
(C) vMAP localizes to the mitochondria. NIH3T3 cells were trans-
fected with pcDNA5-vMAP. At 16 h post-transfection, cells were ﬁxed
and stained with anti-Hsp60 antibody, anti-cytochrome c antibody, or
anti-vMAP serum. A single representative optical section is pre-
sented.
(D) vMAPD20 localizes to the mitochondrion. COS-1 cells transfected
with vMAPD20 expression vector. At 16 h post-transfection, cells were
ﬁxed and stained with mouse anti-cytochrome c antibody (green) and
rabbit anti-vMAP serum (red). A single representative optical section
is presented.
(E) The expression of vMAP and its mutants in NIH3T3 stable cell
lines. Twenty lg of lysates of NIH3T3/puro, NIH3T3/vMAP (wt),
NIH3T3/vMAPD20 (D20), NIH3T3/vMAP L/A (L/A), or NIH3T3/
vMAPD20L/A (D20L/A) cells were analyzed by immunoblotting with
rabbit anti-vMAP serum (top panel) or anti-actin antibody (bottom
panel).
Found at doi:10.1371/journal.ppat.0030174.sg002 (255 KB TIF).
Figure S3. Characterization of vMAP Interaction with Bcl-2 and
Bcl-xL
(A) vMAP interacts with Bcl-2 in 293T cells. Lysates from 293T cells
expressing vMAP and/or HA-Bcl-2 were immunoprecipitated with
anti-HA (Bcl-2) and analyzed by immunoblotting with anti-vMAP
serum (top panel). WCLs were analyzed by immunoblotting with anti-
vMAP serum (middle panel) and anti-HA antibody (bottom panel).
(B) vMAP interacts with the hydrophobic core of Bcl-2. Lysates of
293T cells transfected with HA-Bcl-285–186 together with GST (lane 2)
or vMAP(1–50)-GST (lane 3) were used for GST pull-down, followed
by immunoblotting with anti-HA (Bcl-2, top panel). WCLs were
analyzed by immunoblotting with anti-HA (Bcl-2, middle panel) or
anti-GST (bottom panel) antibodies. Lane 1 indicates 2% of input for
GST pull-down.
(C) Bcl-2 interaction with Bid. At 48 h post-transfection with HA-Bcl-
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with GST (lane 2) or GST-Bid (lane 3) expression vector, 293T cell
lysates were used for GST pull-down, followed by immunoblotting
with anti-HA (Bcl-2, top panel). WCLs were analyzed by immunoblot-
ting with anti-HA (Bcl-2, middle panels) and anti-GST (bottom
panels), respectively. Lane 1 indicates 2% of input for GST pull-
down.
(D) vMAP does not affect the Bcl-xL interaction with Bax. NIH3T3/
puro (lanes 2 and 3) or NIH3T3/vMAP (lane 4) cells were transfected
with HA-Bcl-xL and Flag-Bax expression vectors. WCLs were used for
immunoprecipitation with anti-HA or anti-Myc (control), followed by
immunoblotting with anti-Flag (Bax). WCLs were analyzed by
immunoblotting with anti-HA (Bcl-xL, middle) and anti-Flag (Bax,
bottom panel) antibodies. Lane 1, 5% of input from NIH3T3/puro
cells. Anti-Myc antibody was included as a negative control.
(E) vMAP does not affect the interaction between Bcl-2 and Bax/Bak.
NIH3T3/puro (lanes 1, 2, 4, and 5) and NIH3T3/vMAP (lanes 3 and 6)
cells were transfected with Flag-Bcl-2 and HA-Bax or HA-Bak.
Immunoprecipitation was carried out as described in Figure S3D.
Anti-Myc antibody was included as a negative control for immuno-
precipitation. Protein precipitates were analyzed by immunoblotting
with HRP-conjugated anti-Flag to detect Flag-Bcl-2. WCLs were
analyzed by immunoblotting with anti-HA antibody (HA-Bax or HA-
Bak, middle panels) and anti-Flag antibody (Flag-Bcl-2, bottom
panel).
(F) FRET assay demonstrates that vMAP does not affect the Bcl-2
interaction with Bax. At 36 h post-transfection with pEYFP-Bcl-2 and
pECFP-Bax, NIH3T3/puro cells (Puro), NIH3T3/vMAP cells (vMAP),
and NIH3T3/vMAPD20 cells (vMAPD20) were harvested and subjected
to ﬂow cytometry analysis. Numbers in the FRET diagrams indicate
the percentage of the transfected cell population without protein
interaction (lower right) and the transfected cell population with
protein interaction (upper left). Data represent results from two
independent experiments.
Found at doi:10.1371/journal.ppat.0030174.sg003 (334 KB TIF).
Figure S4. Generation of cHV-68 DvMAP and Its Revertant
(A) Schematic illustrations of cHV-68 wt, cHV-68 DvMAP Kan
R, and
cHV-68 DvMAP. Speciﬁc mutations include T . A changes at the
nucleotide positions of 76016, 76049, and 76076, and a G . A change
at the nucleotide position of 76079 (Entrez accession number
U97553).
(B) Detection of vMAP expression in cHV-68 wt (wt), cHV-68 DvMAP
(DvMAP), or cHV-68 Rev (Rev) infected NIH3T3 cells. NIH3T3 cells
were infected with these recombinant cHV-68 at MOI ¼ 1 and cells
were harvested at 16 h post-infection. Cell lysates were used for
immunoprecipitation with anti-vMAP serum, followed by immuno-
blotting with anti-vMAP serum. Arrow indicates vMAP protein.
(C) Restriction digestion of wt and mutant cHV-68 genomic DNAs.
Genomic DNAs from cHV-68 wt (lane 1), cHV-68 DvMAP (lane 2), or
cHV-68 Rev (lane 3) were puriﬁed by alkaline lysis and ethanol
precipitation, digested with BglII and BamHI, resolved on 0.7%
agarose gel, and photographed.
Found at doi:10.1371/journal.ppat.0030174.sg004 (161 KB TIF).
Figure S5. vMAP Does Not Affect the Bcl-2 with VDAC1 Interaction
Lysates of NIH3T3/puro (lane 1), NIH3T3/vMAP (lane 2), and
NIH3T3/vMAPD20 (lane 3) cells were immunoprecipitated with a
normal rabbit serum or an anti-Bcl-2 rabbit antibody. Protein
precipitates were analyzed by immunoblotting with antibodies to
VDAC1 (top panel), Bcl-2 (middle panel), and anti-vMAP serum (third
panel from top). WCLs were analyzed by immunoblotting with anti-
vMAP serum (bottom panel). H, the heavy chain of IgG.
Found at doi:10.1371/journal.ppat.0030174.sg005 (164 KB TIF).
Accession Numbers
The Entrez Nucleotide (http://www.ncbi.nlm.nih.gov/sites/
entrez?db¼Nucleotide) accession numbers for the sequences dis-
cussed in this paper are vMAP (U97553); human Bcl-2 (NM_000633);
human Bcl-xL (NM_138578); mouse Bax (BC053380); human Bak
(U16811); mouse Bid (U75506); mouse Bad (L37296).
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